학술논문
Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial
Document Type
Article
Author
Michallet, Anne-Sophie ; Dilhuydy, Marie-Sarah; Subtil, Fabien; Rouille, Valerie; Mahe, Beatrice; Laribi, Kamel; Villemagne, Bruno; Salles, Gilles; Tournilhac, Olivier; Delmer, Alain; Portois, Christelle; Pegourie, Brigitte; Leblond, Veronique; Tomowiak, Cecile; de Guibert, Sophie; Orsini, Frederique; Banos, Anne; Carassou, Philippe; Cartron, Guillaume; Fornecker, Luc Mathieu; Ysebaert, Loic; Dartigeas, Caroline; Truchan Graczyk, Malgorzata; Vilque, Jean P; Aurran, Thérèse; Cymbalista, Florence; Lepretre, Stéphane; Lévy, Vincent; Nguyen-Khac, Florence; Le Garff-Tavernier, Magali; Aanei, Carmen; Ticchioni, Michel; Letestu, Rémi; Feugier, Pierre
Source
In The Lancet Haematology September 2019 6(9):e470-e479
Subject
Language
ISSN
2352-3026